Intellia has reported positive results from its ongoing Phase I/II trial of NTLA-2002, a CRISPR-based gene editing therapy ...
ImmunityBio has announced the commencement of a Phase I trial evaluating its CD19 (t-haNK) cell therapy for the treatment of ...
NICE’s decisions for both drugs are not final and are pending more evidence. Credit: Art_Photo via Shutterstock. On 23 ...
Germany-based Ottobock SE & Co. KGaA will hold an approximate 10% stake in Onward’s share capital following the investment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback